Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRAFT: Targeted Therapy and Atezolizumab in Advanced Solid Tumors
NCT04551521Phase 2Completed
- Sponsor
- German Cancer Research Center
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in solid tumor (advanced stage) (7 arms), sponsored by German Cancer Research Center. Primary endpoint: Disease Control Rate at Day 110. Started Oct 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04551521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551521.